{"pmid":32492210,"title":"Tocilizumab Administration in Patients with SARS-CoV-2 Infection: Subcutaneous Injection versus Intravenous Infusion.","text":["Tocilizumab Administration in Patients with SARS-CoV-2 Infection: Subcutaneous Injection versus Intravenous Infusion.","Recent studies have revealed that cytokine storm syndrome, which is caused by the activation of inflammatory cytokines, is a likely underlying pathophysiology in patients with severe COVID-19 that has been associated with a high mortality rate(1) . This article is protected by copyright. All rights reserved.","J Med Virol","Shabani, Minoosh","Shokouhi, Shervin","Moradi, Omid","Saffaei, Ali","Sahraei, Zahra","32492210"],"abstract":["Recent studies have revealed that cytokine storm syndrome, which is caused by the activation of inflammatory cytokines, is a likely underlying pathophysiology in patients with severe COVID-19 that has been associated with a high mortality rate(1) . This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Shabani, Minoosh","Shokouhi, Shervin","Moradi, Omid","Saffaei, Ali","Sahraei, Zahra"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492210","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26124","keywords":["covid-19","cytokine storm syndrome","pharmacokinetic","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892169398648833,"score":9.490897,"similar":[{"pmid":32482373,"title":"Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.","text":["Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.","Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-kappaB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-kappaB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab.","Arch Med Res","Saha, Abinit","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Chakraborty, Chiranjib","32482373"],"abstract":["Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-kappaB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-kappaB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab."],"journal":"Arch Med Res","authors":["Saha, Abinit","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Chakraborty, Chiranjib"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32482373","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.arcmed.2020.05.009","keywords":["covid-19","cytokine storm syndrome","therapeutic option","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668532114882035712,"score":211.77686},{"pmid":32410234,"title":"Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.","text":["Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.","Over the last months, pandemic SARS-CoV-2 caused a significant challenge for clinicians. Unfortunately, no approved and validated treatments are available. Intravenous tocilizumab, an antirheumatic drug, seems to be promising in counteracting cytokine storm caused by SARS-CoV-2 infection with associated clinical improvements. We report herein a case series of patients with COVID-19 pneumonia who were treated with tocilizumab administrated, for the first time, subcutaneously with good clinical and radiological outcomes. This article is protected by copyright. All rights reserved.","J Med Virol","Mazzitelli, Maria","Arrighi, Eugenio","Serapide, Francesca","Pelle, Maria Chiara","Tassone, Bruno","Lionello, Rosaria","Marrazzo, Giuseppina","Lagana, Domenico","Costanzo, Francesco Saverio","Matera, Giovanni","Trecarichi, Enrico Maria","Torti, Carlo","32410234"],"abstract":["Over the last months, pandemic SARS-CoV-2 caused a significant challenge for clinicians. Unfortunately, no approved and validated treatments are available. Intravenous tocilizumab, an antirheumatic drug, seems to be promising in counteracting cytokine storm caused by SARS-CoV-2 infection with associated clinical improvements. We report herein a case series of patients with COVID-19 pneumonia who were treated with tocilizumab administrated, for the first time, subcutaneously with good clinical and radiological outcomes. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Mazzitelli, Maria","Arrighi, Eugenio","Serapide, Francesca","Pelle, Maria Chiara","Tassone, Bruno","Lionello, Rosaria","Marrazzo, Giuseppina","Lagana, Domenico","Costanzo, Francesco Saverio","Matera, Giovanni","Trecarichi, Enrico Maria","Torti, Carlo"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32410234","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1002/jmv.26016","keywords":["covid-19","sars-cov-2","pneumonia","subcutaneous","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666989866091544577,"score":191.92448},{"pmid":32458561,"title":"Lymphopenia in COVID-19: Therapeutic Opportunities.","text":["Lymphopenia in COVID-19: Therapeutic Opportunities.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is uncontrollably spread all over the world. The host immune responses strongly try to confront it with all the potential cells and cytokines. With chronically condition of SARS-CoV-2, NK cells and T cells become exhausted and decreasing their count leads to lymphopenia. Inability to eradicate the infected organ makes hyper-initiation of the immune system, which releases the excessive inflammatory cytokines to compensate the exhausted one as well as the low lymphocytes counts; it consequently lead to the cytokine storm syndrome. These mechanisms and the potential therapeutic targeting are discussed in this paper. This article is protected by copyright. All rights reserved.","Cell Biol Int","Fathi, Nazanin","Rezaei, Nima","32458561"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is uncontrollably spread all over the world. The host immune responses strongly try to confront it with all the potential cells and cytokines. With chronically condition of SARS-CoV-2, NK cells and T cells become exhausted and decreasing their count leads to lymphopenia. Inability to eradicate the infected organ makes hyper-initiation of the immune system, which releases the excessive inflammatory cytokines to compensate the exhausted one as well as the low lymphocytes counts; it consequently lead to the cytokine storm syndrome. These mechanisms and the potential therapeutic targeting are discussed in this paper. This article is protected by copyright. All rights reserved."],"journal":"Cell Biol Int","authors":["Fathi, Nazanin","Rezaei, Nima"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32458561","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/cbin.11403","keywords":["apoptosis","covid-19","coronavirus","cytokine storm syndrome","hypercytokinemia","inflammation","lymphopenia","therapeutic"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667967698924994560,"score":174.20425},{"pmid":32462717,"title":"COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","text":["COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved.","J Med Virol","Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy","32462717"],"abstract":["COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462717","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26078","keywords":["cytokine storm","il6r antagonist","sarilumab","therapeutic option","tocilizumab"],"e_drugs":["tocilizumab","sarilumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521235992576,"score":169.28864},{"pmid":32474885,"title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.","text":["Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.","COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may also occur in some patients. According to current literature, impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis and probable other unknown mechanisms create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm. Various genetic mutations may also constitute a risk factor for severe disease course and occurrence of cytokine storm in COVID-19. Once, immunologic complications like cytokine storm occur, anti-viral treatment alone is not enough and should be combined with appropriate anti-inflammatory treatment. Anti-rheumatic drugs, which are tried for managing immunologic complications of COVID-19 infection, will also be discussed including chloroquine, hydroxychloroquine, JAK inhibitors, IL-6 inhibitors, IL-1 inhibitors, anti-TNF-alpha agents, corticosteroids, intravenous immunoglobulin (IVIG), and colchicine. Early recognition and appropriate treatment of immunologic complications will decrease the morbidity and mortality in COVID-19 infection, which requires the collaboration of infectious disease, lung, and intensive care unit specialists with other experts such as immunologists, rheumatologists, and hematologists.","Clin Rheumatol","Soy, Mehmet","Keser, Gokhan","Atagunduz, Pamir","Tabak, Fehmi","Atagunduz, Isik","Kayhan, Servet","32474885"],"abstract":["COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may also occur in some patients. According to current literature, impairment of SARS-CoV-2 clearance due to genetic and viral features, lower levels of interferons, increased neutrophil extracellular traps, and increased pyroptosis and probable other unknown mechanisms create a background for severe disease course complicated by macrophage activation syndrome and cytokine storm. Various genetic mutations may also constitute a risk factor for severe disease course and occurrence of cytokine storm in COVID-19. Once, immunologic complications like cytokine storm occur, anti-viral treatment alone is not enough and should be combined with appropriate anti-inflammatory treatment. Anti-rheumatic drugs, which are tried for managing immunologic complications of COVID-19 infection, will also be discussed including chloroquine, hydroxychloroquine, JAK inhibitors, IL-6 inhibitors, IL-1 inhibitors, anti-TNF-alpha agents, corticosteroids, intravenous immunoglobulin (IVIG), and colchicine. Early recognition and appropriate treatment of immunologic complications will decrease the morbidity and mortality in COVID-19 infection, which requires the collaboration of infectious disease, lung, and intensive care unit specialists with other experts such as immunologists, rheumatologists, and hematologists."],"journal":"Clin Rheumatol","authors":["Soy, Mehmet","Keser, Gokhan","Atagunduz, Pamir","Tabak, Fehmi","Atagunduz, Isik","Kayhan, Servet"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474885","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s10067-020-05190-5","keywords":["covid-19","cytokine storm syndrome","hemophagocytic lymphohistiocytosis","macrophage activation syndrome"],"locations":["Cytokine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668341932687884289,"score":149.26018}]}